Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic Syndrome

Autores
Renna, Nicolas Federico; Diez, Emiliano Raúl; Lembo, Carina; Miatello, Roberto Miguel
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The objective of this work was to demonstrate the role of COX-2 enzyme at the vascular in experimental model of metabolic syndrome. SHR male WKY rats were employed; they were distributed in 8 groups (N = 8 each): control (W); W + L: WKY rats receiving 20mg/kg of lumiracoxib by intraesophageal administration; SHR; SHR + L: SHR + 20mg/kg of lumiracoxib by intraesophageal administration; Fructose-Fed Rats (FFR):WKYrats receiving 10% (w/v) fructose solution in drinking water during all 12 weeks; FFR + L: FFR + 20mg/kg of lumiracoxib by intraesophageal administration; Fructose-Fed Hypertensive Rats (FFHR): SHR receiving 10% (w/v) fructose solution in drinking water during all 12 weeks; and FFHR + L: FFHR + 20mg/kg of lumiracoxib by intraesophageal administration.Metabolic variables, blood pressure,morphometric variables, and oxidative stress variables were evaluated; alsoMMP-2 andMMP-9 (collagenases), VCAM-1, and NF-B byWesternblot or IFI were evaluated. FFHR presented all variables of metabolic syndrome; there was also an increase in oxidative stress variables; vascular remodeling and left ventricular hypertrophy were evidenced along with a significant increase in the expression of the mentioned proinflammatory molecules and increased activity and expression of collagenase. Lumiracoxib was able to reverse vascular remodeling changes and inflammation, demonstrating the involvement of COX-2 in the pathophysiology of vascular remodeling in this experimental model.
Fil: Renna, Nicolas Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico - CONICET - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina; Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Departamento de Patología; Argentina;
Fil: Diez, Emiliano Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico - CONICET - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina; Universidad Nacional de Cuyo; Argentina;
Fil: Lembo, Carina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico - CONICET - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina;
Fil: Miatello, Roberto Miguel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico - CONICET - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina; Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Departamento de Patología; Argentina;
Materia
MMP-2 MMP-9
FRUCTOSE-FED HYPERTENSIVE RATS
VASCULAR REMODELING AND INFLAMMATION
COX-2
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/1867
Acceder
id CONICETDig_df649330f3dd4093d45e37adcf423166
oai_identifier_str oai:ri.conicet.gov.ar:11336/1867
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic SyndromeRenna, Nicolas FedericoDiez, Emiliano RaúlLembo, CarinaMiatello, Roberto MiguelMMP-2 MMP-9FRUCTOSE-FED HYPERTENSIVE RATSVASCULAR REMODELING AND INFLAMMATIONCOX-2https://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3The objective of this work was to demonstrate the role of COX-2 enzyme at the vascular in experimental model of metabolic syndrome. SHR male WKY rats were employed; they were distributed in 8 groups (N = 8 each): control (W); W + L: WKY rats receiving 20mg/kg of lumiracoxib by intraesophageal administration; SHR; SHR + L: SHR + 20mg/kg of lumiracoxib by intraesophageal administration; Fructose-Fed Rats (FFR):WKYrats receiving 10% (w/v) fructose solution in drinking water during all 12 weeks; FFR + L: FFR + 20mg/kg of lumiracoxib by intraesophageal administration; Fructose-Fed Hypertensive Rats (FFHR): SHR receiving 10% (w/v) fructose solution in drinking water during all 12 weeks; and FFHR + L: FFHR + 20mg/kg of lumiracoxib by intraesophageal administration.Metabolic variables, blood pressure,morphometric variables, and oxidative stress variables were evaluated; alsoMMP-2 andMMP-9 (collagenases), VCAM-1, and NF-B byWesternblot or IFI were evaluated. FFHR presented all variables of metabolic syndrome; there was also an increase in oxidative stress variables; vascular remodeling and left ventricular hypertrophy were evidenced along with a significant increase in the expression of the mentioned proinflammatory molecules and increased activity and expression of collagenase. Lumiracoxib was able to reverse vascular remodeling changes and inflammation, demonstrating the involvement of COX-2 in the pathophysiology of vascular remodeling in this experimental model.Fil: Renna, Nicolas Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico - CONICET - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina; Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Departamento de Patología; Argentina;Fil: Diez, Emiliano Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico - CONICET - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina; Universidad Nacional de Cuyo; Argentina;Fil: Lembo, Carina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico - CONICET - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina;Fil: Miatello, Roberto Miguel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico - CONICET - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina; Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Departamento de Patología; Argentina;Hindawi Publishing Corporation2013-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/1867Renna, Nicolas Federico; Diez, Emiliano Raúl; Lembo, Carina; Miatello, Roberto Miguel; Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic Syndrome; Hindawi Publishing Corporation; Mediators of Inflammation; 2013; 2-2013; 1-100962-9351enginfo:eu-repo/semantics/altIdentifier/url/http://www.hindawi.com/journals/mi/2013/513251/info:eu-repo/semantics/altIdentifier/doi/10.1155/2013/513251info:eu-repo/semantics/altIdentifier/url/http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586490/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:52:13Zoai:ri.conicet.gov.ar:11336/1867instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:52:13.828CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic Syndrome
title Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic Syndrome
spellingShingle Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic Syndrome
Renna, Nicolas Federico
MMP-2 MMP-9
FRUCTOSE-FED HYPERTENSIVE RATS
VASCULAR REMODELING AND INFLAMMATION
COX-2
title_short Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic Syndrome
title_full Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic Syndrome
title_fullStr Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic Syndrome
title_full_unstemmed Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic Syndrome
title_sort Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic Syndrome
dc.creator.none.fl_str_mv Renna, Nicolas Federico
Diez, Emiliano Raúl
Lembo, Carina
Miatello, Roberto Miguel
author Renna, Nicolas Federico
author_facet Renna, Nicolas Federico
Diez, Emiliano Raúl
Lembo, Carina
Miatello, Roberto Miguel
author_role author
author2 Diez, Emiliano Raúl
Lembo, Carina
Miatello, Roberto Miguel
author2_role author
author
author
dc.subject.none.fl_str_mv MMP-2 MMP-9
FRUCTOSE-FED HYPERTENSIVE RATS
VASCULAR REMODELING AND INFLAMMATION
COX-2
topic MMP-2 MMP-9
FRUCTOSE-FED HYPERTENSIVE RATS
VASCULAR REMODELING AND INFLAMMATION
COX-2
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The objective of this work was to demonstrate the role of COX-2 enzyme at the vascular in experimental model of metabolic syndrome. SHR male WKY rats were employed; they were distributed in 8 groups (N = 8 each): control (W); W + L: WKY rats receiving 20mg/kg of lumiracoxib by intraesophageal administration; SHR; SHR + L: SHR + 20mg/kg of lumiracoxib by intraesophageal administration; Fructose-Fed Rats (FFR):WKYrats receiving 10% (w/v) fructose solution in drinking water during all 12 weeks; FFR + L: FFR + 20mg/kg of lumiracoxib by intraesophageal administration; Fructose-Fed Hypertensive Rats (FFHR): SHR receiving 10% (w/v) fructose solution in drinking water during all 12 weeks; and FFHR + L: FFHR + 20mg/kg of lumiracoxib by intraesophageal administration.Metabolic variables, blood pressure,morphometric variables, and oxidative stress variables were evaluated; alsoMMP-2 andMMP-9 (collagenases), VCAM-1, and NF-B byWesternblot or IFI were evaluated. FFHR presented all variables of metabolic syndrome; there was also an increase in oxidative stress variables; vascular remodeling and left ventricular hypertrophy were evidenced along with a significant increase in the expression of the mentioned proinflammatory molecules and increased activity and expression of collagenase. Lumiracoxib was able to reverse vascular remodeling changes and inflammation, demonstrating the involvement of COX-2 in the pathophysiology of vascular remodeling in this experimental model.
Fil: Renna, Nicolas Federico. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico - CONICET - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina; Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Departamento de Patología; Argentina;
Fil: Diez, Emiliano Raúl. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico - CONICET - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina; Universidad Nacional de Cuyo; Argentina;
Fil: Lembo, Carina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico - CONICET - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina;
Fil: Miatello, Roberto Miguel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico - CONICET - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina; Universidad Nacional de Cuyo. Facultad de Ciencias Médicas. Departamento de Patología; Argentina;
description The objective of this work was to demonstrate the role of COX-2 enzyme at the vascular in experimental model of metabolic syndrome. SHR male WKY rats were employed; they were distributed in 8 groups (N = 8 each): control (W); W + L: WKY rats receiving 20mg/kg of lumiracoxib by intraesophageal administration; SHR; SHR + L: SHR + 20mg/kg of lumiracoxib by intraesophageal administration; Fructose-Fed Rats (FFR):WKYrats receiving 10% (w/v) fructose solution in drinking water during all 12 weeks; FFR + L: FFR + 20mg/kg of lumiracoxib by intraesophageal administration; Fructose-Fed Hypertensive Rats (FFHR): SHR receiving 10% (w/v) fructose solution in drinking water during all 12 weeks; and FFHR + L: FFHR + 20mg/kg of lumiracoxib by intraesophageal administration.Metabolic variables, blood pressure,morphometric variables, and oxidative stress variables were evaluated; alsoMMP-2 andMMP-9 (collagenases), VCAM-1, and NF-B byWesternblot or IFI were evaluated. FFHR presented all variables of metabolic syndrome; there was also an increase in oxidative stress variables; vascular remodeling and left ventricular hypertrophy were evidenced along with a significant increase in the expression of the mentioned proinflammatory molecules and increased activity and expression of collagenase. Lumiracoxib was able to reverse vascular remodeling changes and inflammation, demonstrating the involvement of COX-2 in the pathophysiology of vascular remodeling in this experimental model.
publishDate 2013
dc.date.none.fl_str_mv 2013-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/1867
Renna, Nicolas Federico; Diez, Emiliano Raúl; Lembo, Carina; Miatello, Roberto Miguel; Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic Syndrome; Hindawi Publishing Corporation; Mediators of Inflammation; 2013; 2-2013; 1-10
0962-9351
url http://hdl.handle.net/11336/1867
identifier_str_mv Renna, Nicolas Federico; Diez, Emiliano Raúl; Lembo, Carina; Miatello, Roberto Miguel; Role of Cox-2 in Vascular Inflammation: An Experimental Model of Metabolic Syndrome; Hindawi Publishing Corporation; Mediators of Inflammation; 2013; 2-2013; 1-10
0962-9351
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.hindawi.com/journals/mi/2013/513251/
info:eu-repo/semantics/altIdentifier/doi/10.1155/2013/513251
info:eu-repo/semantics/altIdentifier/url/http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586490/
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Hindawi Publishing Corporation
publisher.none.fl_str_mv Hindawi Publishing Corporation
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269144573018112
score 13.13397

Publicaciones similares